Immediate therapeutic opportunities may involve targeting ApoA-V to regulate TG metabolism for stroke prevention, especially in individuals with genetic risk factors, and exploring the role of ApoA-I in amyloid clearance in Alzheimer’s disease. The gene discussed is APOA5; the disease is stroke disorder.